Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers said it will begin offering all dose sizes of Wegovy along with access to 24/7 care, nutritional guidance and ongoing clinical support this week, starting at $599 per month to eligible ...

In May 2024, Hims & Hers began offering access to GLP-1s, first in the form of compounded injectable semaglutide, and in August 2024 in the form of branded (or FDA approved) injectable semaglutide.

SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s ...

SAN FRANCISCO, CA / ACCESS Newswire / July 21, 2025 / On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE:HIMS)and certain of the company's executives.